- Home
- AYTU vs APM Comparison
AYTU vs APM Comparison
Compare AYTU & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- APM
- Stock Information
- Founded
- AYTU N/A
- APM 2010
- Country
- AYTU United States
- APM United Kingdom
- Employees
- AYTU N/A
- APM N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- APM Health Care
- Exchange
- AYTU Nasdaq
- APM Nasdaq
- Market Cap
- AYTU 19.7M
- APM 18.9M
- IPO Year
- AYTU N/A
- APM 2018
- Fundamental
- Price
- AYTU $2.37
- APM $1.92
- Analyst Decision
- AYTU Strong Buy
- APM
- Analyst Count
- AYTU 2
- APM 0
- Target Price
- AYTU $10.00
- APM N/A
- AVG Volume (30 Days)
- AYTU 100.5K
- APM 20.5M
- Earning Date
- AYTU 11-12-2025
- APM 04-30-2025
- Dividend Yield
- AYTU N/A
- APM N/A
- EPS Growth
- AYTU N/A
- APM N/A
- EPS
- AYTU N/A
- APM N/A
- Revenue
- AYTU $81,659,000.00
- APM N/A
- Revenue This Year
- AYTU N/A
- APM N/A
- Revenue Next Year
- AYTU $2.00
- APM N/A
- P/E Ratio
- AYTU N/A
- APM N/A
- Revenue Growth
- AYTU 0.41
- APM N/A
- 52 Week Low
- AYTU $0.95
- APM $0.46
- 52 Week High
- AYTU $2.85
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- AYTU 55.75
- APM 51.65
- Support Level
- AYTU $2.21
- APM $1.79
- Resistance Level
- AYTU $2.58
- APM $2.02
- Average True Range (ATR)
- AYTU 0.13
- APM 0.16
- MACD
- AYTU 0.01
- APM -0.03
- Stochastic Oscillator
- AYTU 48.78
- APM 45.98
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.